T. Botton

发表

CNVkit: Copy number detection and visualization for targeted sequencing using off-target reads

B. Bastian, E. Talevich, A. Shain, 2014, bioRxiv.

Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny

P. Bahadoran, C. Bertolotto, R. Ballotti, 2011, Oncogene.

Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway

Nam Huh, Iwei Yeh, Eric Talevich, 2015, Nature Genetics.

Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion.

E. Collisson, S. Behr, R. Kelley, 2018, The oncologist.

Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation.

Robert L. Judson, Robert L Judson, Jue Lin, 2018, Cancer cell.

In vitro and in vivo anti-melanoma effects of ciglitazone.

P. Bahadoran, J. Ortonne, C. Bertolotto, 2009, The Journal of investigative dermatology.

NTRK3 kinase fusions in Spitz tumours

I. Yeh, B. Bastian, P. Leboit, 2016, The Journal of pathology.

Activating MET Kinase Rearrangements in Melanoma and Spitz Tumors

I. Yeh, B. Bastian, P. Leboit, 2015, Nature Communications.

Kinase fusions are frequent in Spitz tumours and spitzoid melanomas

Iwei Yeh, Doron Lipson, Thomas Wiesner, 2014, Nature Communications.

CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing

Eric Talevich, A. Hunter Shain, Thomas Botton, 2016, PLoS Comput. Biol..

Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion

I. Yeh, R. Scolyer, G. Long, 2015, Pigment cell & melanoma research.

Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy

Iwei Yeh, Gideon Bollag, Thomas Botton, 2013, Pigment cell & melanoma research.

Discovery of a new molecule inducing melanoma cell death: dual AMPK/MELK targeting for novel melanoma therapies

P. Abbe, R. Ballotti, F. Bost, 2021, Cell death & disease.

Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance.

P. Abbe, C. Bertolotto, R. Ballotti, 2016, Cancer cell.

Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth

J. Ortonne, C. Bertolotto, R. Ballotti, 2011, Cell Death and Differentiation.

Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny

P. Bahadoran, C. Bertolotto, R. Ballotti, 2011, Oncogene.

Metformin inhibits melanoma development through autophagy and apoptosis mechanisms

P. Bahadoran, C. Bertolotto, R. Ballotti, 2011, Cell Death and Disease.

Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses.

Robert L. Judson, K. Brown, N. Hayward, 2019, Cell reports.

Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance.

P. Abbe, C. Bertolotto, R. Ballotti, 2016, Cancer cell.

Melanoma BRAF Fusions—Letter

I. Yeh, B. Bastian, T. Botton, 2014, Clinical Cancer Research.

Rac1 Dynamics in the Human Opportunistic Fungal Pathogen Candida albicans

R. Arkowitz, T. Botton, M. Bassilana, 2010, PloS one.

Comment on ‘Testing for BRAF fusions in patients with advanced BRAF/NRAS/KIT wild-type melanomas permits to identify patients who could benefit of anti-MEK targeted therapy’

S. Rocchi, T. Botton, T. Passeron, 2019, Journal of Clinical Pathology.

Supporting Methods

B. Bastian, A. Shain, T. Botton, 2003 .

Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy

I. Yeh, P. Bahadoran, R. Ballotti, 2013, Pigment cell & melanoma research.

Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth

C. Bertolotto, R. Ballotti, S. Rocchi, 2011, Cell Death and Differentiation.

Supporting Methods

B. Bastian, A. Shain, T. Botton, 2016 .